Had AstraZeneca or Phizer achieved these impressive results had they been in control of ABL, would they have just sat on their laurels so too speak?

"About BETonMACE and BETonMACE2

In the fall of 2019, Resverlogix reported results from its Phase 3 trial BETonMACE, which tested the beneficial impact of apabetalone treatment on MACE, in a population of 2,425 CVD patients with diabetes and a recent acute coronary syndrome event. The trial found a hazard reduction (HR) of 18% in its primary endpoint – a composite of first MI, stroke and CV death – with apabetalone treatment, when compared to placebo with top standard of care which just missed statistical significance (p=0.11). The HR was improved to 22% when the composite endpoint was broadened post-hoc to include first hospitalization due to congestive heart failure (MACE+CHF) which was significant. In the pre-specified chronic kidney disease sub population, the observed apabetalone benefits were even more dramatic, with statistically significant reductions in both MACE (HR=50%) and MACE+CHF (HR=52%).  Apabetalone’s consistent safety profile was further validated by an analysis of adverse events in BETonMACE, and nine positive reports by the trial’s independent Data and Safety Monitoring Board."

Just saying ... Koo